Yufan Ying

ORCID: 0000-0002-8552-9557
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Epigenetics and DNA Methylation
  • Cancer-related gene regulation
  • MicroRNA in disease regulation
  • Circular RNAs in diseases
  • Bladder and Urothelial Cancer Treatments
  • Ferroptosis and cancer prognosis
  • RNA Research and Splicing
  • Urinary and Genital Oncology Studies
  • Renal cell carcinoma treatment
  • HVDC Systems and Fault Protection
  • Cancer Immunotherapy and Biomarkers
  • FOXO transcription factor regulation
  • RNA and protein synthesis mechanisms
  • Cancer, Lipids, and Metabolism
  • Viral-associated cancers and disorders
  • Kruppel-like factors research
  • Cardiovascular Disease and Adiposity
  • Adipokines, Inflammation, and Metabolic Diseases
  • Prostate Cancer Treatment and Research
  • Metastasis and carcinoma case studies
  • Peroxisome Proliferator-Activated Receptors
  • Immune cells in cancer
  • Genetic Syndromes and Imprinting

First Affiliated Hospital Zhejiang University
2018-2024

Zhejiang University
2017-2024

Zhejiang Cancer Hospital
2021

N6-methyladenosine (m6A) is the most abundant modification in mRNA of humans. Emerging evidence has supported fact that m6A comprehensively involved various diseases especially cancers. As a crucial reader, YTHDF2 usually mediates degradation m6A-modified mRNAs m6A-dependent way. However, function and mechanisms prostate cancer (PCa) still remain elusive.To investigate functions PCa, vitro, vivo biofunctional assays epigenetics experiments were performed. Endogenous expression silencing...

10.1186/s12943-020-01267-6 article EN cc-by Molecular Cancer 2020-10-29

Abstract N6‐Methyladenosine (m 6 A) modification, the most prevalent modification of eukaryotic messenger RNA (mRNA), is involved in progression various tumours. However, specific role m A bladder cancer (BCa) still poorly understood. In this study, we demonstrated tumour‐promoting function and regulatory mechanism axis, consisting core ‘writer’ protein METTL3 major reader YTHDF2. Depletion impaired proliferation metastasis vitro vivo. Through transcriptome sequencing, methylated...

10.1111/jcmm.15063 article EN cc-by Journal of Cellular and Molecular Medicine 2020-03-03

Emerging discoveries of dynamic and reversible N6-methyladenosine (m6A) modification on RNA in mammals have revealed the key roles human tumorigenesis. As known m6A readers, insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) are upregulated most cancers mediates enhancement m6A-modified mRNAs stability. However, mechanisms IGF2BPs renal cell cancer (RCC) still remain unclear. Bioinformatic analysis RT-qPCR were performed to evaluate expression writer Wilms tumor 1-associating...

10.1038/s41419-021-04038-3 article EN cc-by Cell Death and Disease 2021-07-29

Several studies have indicated that circular RNAs (circRNAs) play vital roles in the progression of various diseases, including bladder cancer (BCa). However, underlying mechanisms by which circRNAs drive BCa malignancy remain unclear. In this study, we identified a novel circRNA, circPSMA7 (circbaseID:has_circ_0003456), showing increased expression cell lines and tissues, integrating reported information with circRNA-seq qRT-PCR. We revealed is associated higher tumor grade stage BCa. M

10.1016/j.canlet.2024.216613 article EN cc-by Cancer Letters 2024-01-09

ABSTRACT Emerging evidence has elucidated that microRNAs (miRNAs) transcribed from miRNA cluster at DLK‐DIO3 imprinted domain are involved in various cancers. However, as one member of this cluster, the underlying mechanisms and functions miR‐381‐3p bladder cancer (BCa) still remains elusive. Here we demonstrate hypermethylated status upstream maternally expressed gene 3 divergent methylation region reduces expression BCa by bisulfite‐sequencing PCR. In vitro vivo experiments indicate...

10.1096/fj.201800667r article EN The FASEB Journal 2018-08-23

Downregulation of miR-502-5p has emerged as a critical factor in tumour progression several cancers. Herein, we elucidated the role bladder cancer.RT-qPCR was performed to examine expression cancer. And DNA methylation analysis showed that epigenetic mechanisms may contribute downregulation miR-502-5p. Then, wound-healing assay, transwell colony formation CCK8 assay and flow cytometry were applied evaluate function cancer cell lines. Western blot conducted measure protein levels related...

10.1111/cpr.12751 article EN Cell Proliferation 2020-01-23

Clear cell renal carcinoma (ccRCC) is one of the tumor types with sensitivity to ferroptosis, and immunotherapy has emerged as a standard pillar for metastatic ccRCC treatment, while it remains largely obscure whether ferroptosis influences immune microenvironment in ccRCC. Based on available data The Cancer Genome Atlas, divergent expression profiles regulators were noted normal tissues, we also found that correlated PD-L1 expression. Two independent subtypes determined by consensus...

10.3389/fcell.2021.676142 article EN cc-by Frontiers in Cell and Developmental Biology 2021-07-05

Background: Bladder cancer (BC) represents a common malignancy and is characterized by high heterogeneity complex biological behaviors, which pose substantial challenges to its effective treatment. Mounting evidence highlights the pivotal roles of ribonucleic acid (RNA) modifications, particularly N6-methyladenosine, alongside others such as 1-methyladenosine, 5-methylcytosine, N4-acetylcytidine, 7-methylguanosine, in regulation proliferation, migration, drug resistance, immune evasion BC...

10.14440/bladder.2024.0062 article EN Bladder 2025-03-06

Abstract Background Emerging evidence suggests that miR‐501‐3p plays an important role in the pathogenesis and progression of various carcinomas. However, its underlying mechanisms renal cell carcinoma (RCC) remain to be elucidated. Methods Quantitative RT‐PCR, western blot, bioinformatics methods were used evaluate expression Wilms’ tumor 1‐associating protein ( WTAP ) RCC lines clinical tissues. The effects on proliferation cells investigated using flow cytometric, colony formation, CCK8...

10.1002/cam4.4157 article EN cc-by Cancer Medicine 2021-09-30

Emerging research indicates that miRNAs can regulate cancer progression by influencing molecular pathways. Here, we studied miR-665, part of the DLK1-DIO3 miRNA cluster, which is downregulated upstream methylation in bladder cancer. MiR-665 overexpression significantly expression SMAD3, phospho-SMAD3, and SNAIL, reversed epithelial-mesenchymal transition progression, inhibited migration cells. To predict potential targets used online databases subsequently determined miR-665 binds directly...

10.1080/15384101.2021.1929677 article EN Cell Cycle 2021-07-01

Emerging research has suggested that miRNAs play a significant role in oncogenesis and tumor progression by regulating multiple molecular pathways. Here, we investigated miR-300, which inhibited bladder cancer (BCa) migration the SP1/MMP9 pathway. belonging to DLK1-DIO3 miRNA cluster, is frequently expressed at lower levels BCa tissue than adjacent normal due DNA methylation. Reinforced expression of miR-300 significantly suppressed cells. We carried out search online databases predict...

10.1080/15384101.2018.1557490 article EN Cell Cycle 2018-12-10

Circular RNAs (circRNAs) play essential roles in human bladder cancer (BCa) development, however, unusual expression patterns and functional dysfunction of circRNAs BCa have not been evaluated. In this study, we validated that circKDM4C (hsa_circ_0001839), derived from the KDM4C gene, is elevated cell lines as well tissues. Functionally, overexpression significantly enhances, silencing suppresses migration invasion capabilities cells. Mechanistically, can directly interact with miR-200b-3p...

10.1038/s41420-021-00712-9 article EN cc-by Cell Death Discovery 2021-11-23

Abstract Background Aryl hydrocarbon receptor nuclear translocator like 2 (ARNTL2) is a member of the PAS superfamily. Previous studies explored carcinogenic roles transcription factor ARNTL2 in human malignancies. However, its ccRCC have not been elucidated. This study sought to explore and determine correlations with tumor immunity. Methods The expression was analyzed using GEO, TCGA GTEx database, verified tissue samples cell lines by qRT-PCR western blot analysis. Kaplan–Meier survival...

10.1186/s12935-021-02046-z article EN cc-by Cancer Cell International 2021-07-03

Previous research evidence suggests that microRNAs (miRNAs) play an indispensable role in onset and progression of bladder cancer (BCa). Here, we explored the functions mechanisms miR-5581-3p BCa. miR-5581-3p, as a tumor suppressor BCa, was detected at lower expression level BCa tissue cells contrast with non-malignant cells. Over-expression remarkably dampened migration proliferation vitro vivo. SMAD3 FTO were identified direct targets by online databases prediction mRNA-seq, which further...

10.1038/s41420-022-01010-8 article EN cc-by Cell Death Discovery 2022-04-13

FTO, as an m6A mRNA demethylase, is involved in various cancers. However, the role of FTO clear cell renal carcinoma (ccRCC) remains unclear. In present study, we discovered upregulated ccRCC. Functionally, knockdown significantly impairs proliferation and migration ability ccRCC cells. Mechanistically, our data suggest promotes through preventing degradation PDK1 induced by YTHDF2 m6A-dependent mechanism. Overall, results identify protumorigenic m6A/YTHDF2/PDK1 pathway, which could be a...

10.1038/s41420-022-01151-w article EN cc-by Cell Death Discovery 2022-08-12

Kruppel like factor 4 (KLF4), a transcription associated with carcinogenesis and tumor progression, plays an important role in various malignancies. In the present study, we utilized CRISPR-ON system to upregulate KLF4 expression level subsequently investigated effect mechanism of progression urothelial bladder cancer (UBC). Immunohistochemistry (IHC) quantitative RT-PCR (qRT-PCR) were used evaluate KLF4. The CpG methylation status promoter region was analyzed using bisulfite-sequencing PCR...

10.18632/oncotarget.22158 article EN Oncotarget 2017-10-27
Coming Soon ...